Navigation Links
Pharma IQ's Solubility Report

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and experience of other industries to help aid solubility improvement in pharmaceuticals with new updates from Zhijun Liu
    Professor, Medicinal Plant Lab, School of Renewable Natural Resources
    Louisiana State University Agricultural Centre

To access more reports or to find out more about Pharmaceutical Distribution 2011 please visit, email or call +44(0)207-368-1300.

Media contact: Joanna Checinska, +44(0)20-7368-9421, - Please contact for more information or images.

Press are invited to attend this important industry forum, if you would like a complimentary press pass please email Joanna Checinska (

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
Breaking Medicine News(10 mins):